Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.75 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 7/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.53 |
| ▸ | ESR1 | P03372 | 4/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26241763 | 0.91 | L3MBTL1 (0.79) | L3MBTL1GAAMAPTALDH1A1LMNA | |
| SCHEMBL8488482 | 0.89 | L3MBTL1 (0.82) | L3MBTL1GAAMAPTALDH1A1LMNA | |
| SCHEMBL834525 | 0.88 | L3MBTL1 (0.88) | L3MBTL1GAAMAPTALDH1A1LMNA | |
| SCHEMBL19257733 | 0.87 | GAA (0.83) | L3MBTL1GAAMAPTALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL19209319 | 0.86 | GAA (0.80) | L3MBTL1GAAMAPTALDH1A1LMNA | |
| SCHEMBL18868405 | 0.86 | L3MBTL1 (1.00) | L3MBTL1GAAMAPTALDH1A1LMNA | |
| SCHEMBL3046764 | 0.85 | L3MBTL1 (0.75) | L3MBTL1GAAMAPTALDH1A1LMNA | |
| SCHEMBL7738999 | 0.83 | GAA (0.75) | L3MBTL1GAAMAPTALDH1A1LMNA | |
| SCHEMBL8672706 | 0.82 | L3MBTL1 (0.78) | L3MBTL1GAAMAPTALDH1A1LMNA | |
| SCHEMBL1092185 | 0.82 | L3MBTL1 (0.85) | L3MBTL1GAAMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2016-12-08 | — | — | US | claimed |
| EP-2033662-B1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2012-10-17 | — | — | EP | claimed |
| EP-2368579-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2011-09-28 | — | — | EP | claimed |
| US-20100009917-A1 | Modulating Enzymatic Processes by Addition of Diolcontaining Substances | NOVO NORDISK HEALTH CARE AG (CH) | 2010-01-14 | — | — | US | claimed |
| EP-2121952-A1 | MODULATING ENZYMATIC PROCESSES BY ADDITION OF DIOLCONTAINING SUBSTANCES | Novo Nordisk Health Care AG (CH) | 2009-11-25 | — | — | EP | claimed |
| US-20090264366-A1 | Transglutaminase Mediated Conjugation of Peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2009-10-22 | — | — | US | claimed |
| EP-2033662-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2009-03-11 | — | — | EP | claimed |
| WO-2008101957-A1 | MODULATING ENZYMATIC PROCESSES BY ADDITION OF DIOLCONTAINING SUBSTANCES | NOVO NORDISK HEALTH CARE AG (DK) | 2008-08-28 | — | — | WO | claimed |
| JP-2007518747-A | — | — | 2007-07-12 | — | — | JP | claimed |
| US-20070105770-A1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-10 | — | — | US | claimed |
| EP-1708755-A2 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2006-10-11 | — | — | EP | claimed |
| WO-2005070468-A2 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2005-08-04 | — | — | WO | claimed |
| WO-2023171448-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASE TO BE PREVENTED OR TREATED BY DEACTIVATION OF MYOFIBROBLASTS | 学校法人東海大学 | 2023-09-14 | — | — | WO | disclosed |
| EP-2842576-B1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2017-06-28 | — | — | EP | disclosed |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2016-12-08 | — | — | US | disclosed |
| EP-2842576-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2015-03-04 | — | — | EP | disclosed |
| WO-2008101957-A1 | MODULATING ENZYMATIC PROCESSES BY ADDITION OF DIOLCONTAINING SUBSTANCES | NOVO NORDISK HEALTH CARE AG (DK) | 2008-08-28 | — | — | WO | disclosed |
| US-20070105770-A1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-10 | — | — | US | disclosed |
| EP-1708755-A2 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005070468-A2 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264366-A1 | Transglutaminase Mediated Conjugation of Peptides | TGM2, TGM3, TGM1 | L3MBTL1 2581/4885GAA 78/4885MAPT 2315/4885 |
| US-20100009917-A1 | Modulating Enzymatic Processes by Addition of Diolcontaining Substances | HSD17B14, CES2, PNLIP | L3MBTL1 4773/4885GAA 8/4885MAPT 4178/4885 |
| US-20070105770-A1 | Transglutaminase mediated conjugation of peptides | TGM2, TGM3, TGM1 | L3MBTL1 2581/4885GAA 78/4885MAPT 2315/4885 |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | TGM2, TGM3, TGM1 | L3MBTL1 2581/4885GAA 78/4885MAPT 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.